Status:
COMPLETED
Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia
Lead Sponsor:
University of Bremen
Collaborating Sponsors:
German Federal Ministry of Education and Research
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
This study is designed to compare the efficacy and drug tolerability of two strategies for the treatment of schizophrenia. The two strategies consist of utilizing, on the one hand, a conventional anti...
Detailed Description
There is agreement in the psychiatry community that the so-called atypical antipsychotics should be considered first choice in the treatment of schizophrenic disorders. However, the general superiorit...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Schizophrenia
- age 18-65 years
- necessity to establish new or change antipsychotic treatment due to unsatisfying results or side effects
- written informed consent
- Exclusion Criteria (amongst others):
- Known or suspected hypersensitivity to olanzapine, quetiapine, aripiprazole, flupentixol or haloperidol
- Acute suicidal tendency
- "Einwilligungsvorbehalt (BGB)" or "Unterbringung (PsychKG)"
- Epilepsy
- Organic psychosis
- Parkinson Disease
- Dementia
- History of malignant neuroleptic syndrome
- QTc interval ≥ 0.5s / history of congenital QTc prolongation
Exclusion
Key Trial Info
Start Date :
February 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2014
Estimated Enrollment :
149 Patients enrolled
Trial Details
Trial ID
NCT01164059
Start Date
February 1 2010
End Date
March 1 2014
Last Update
June 22 2015
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsklinikum Aachen
Aachen, Germany
2
Krankenhaus Angermünde
Angermünde, Germany
3
Karl-Jaspers-Klinik
Bad Zwischenahn, Germany
4
Charité - Universitätsmedizin Berlin
Berlin, Germany